MNTA News Alert Momenta Pharmaceuticals (MNTA) 11.00 12/16/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Momenta Pharmaceuticals (MNTA) 11.00 $MNTA

Insider Trading Alert - DIN, AER And MNTA Traded By Insiders
at The Street - Mon Dec 15, 9:10AM CST
Stocks with insider trader activity include DIN, AER and MNTA
AER: 37.08 (-0.88), MNTA: 11.00 (-0.43), DIN: 96.87 (-2.85)

Teva Upgraded On Strength Of Copaxone MS Drug
at Investor's Business Daily - Fri Dec 12, 9:38AM CST
Sterne Agee upgraded Israeli drug giant Teva Pharmaceutical Industries (TEVA) to buy from neutral Friday, saying the outlook for its multiple-sclerosis drug Copaxone is better than most investors think. Teva issued 2015 guidance on Thursday morning,...
MYL: 53.56 (-0.96), TEVA: 55.15 (-0.47), MNTA: 11.00 (-0.43), NVS: 91.65 (+0.01)

Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.35 (-0.17), LXRX: 0.86 (+0.01), LLY: 69.26 (-0.41), GSK: 41.92 (+0.62), MNTA: 11.00 (-0.43)

Insider Trading Alert - NUVA, MNTA And AKR Traded By Insiders
at The Street - Wed Dec 03, 9:15AM CST
Stocks with insider trader activity include NUVA, MNTA and AKR
AKR: 31.04 (-0.06), MNTA: 11.00 (-0.43), NUVA: 45.13 (-0.26)

Momenta's Necuparanib Gets Fast Track Status in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 2:10PM CST
Momenta Pharmaceuticals, Inc.'s (MNTA) necuparanib (plus Abraxane and Gemzar) received fast track designation from the FDA for metastatic pancreatic cancer.
BIIB: 325.13 (-10.67), BAX: 70.73 (-0.37), ABBV: 65.25 (-0.37), MNTA: 11.00 (-0.43)

Insider Trading Alert - SUBK, PDCO And MNTA Traded By Insiders
at The Street - Tue Dec 02, 9:17AM CST
Stocks with insider trader activity include SUBK, PDCO and MNTA
PDCO: 47.12 (-0.02), SUBK: 21.20 (+0.21), MNTA: 11.00 (-0.43)

Momenta cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 10:24AM CST

MNTA: 11.00 (-0.43)

Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer
GlobeNewswire - Mon Dec 01, 7:15AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib, the Company's novel oncology drug candidate, as a first-line treatment in combination with Abraxaneand gemcitabine in patients with metastatic pancreatic cancer. Momenta recently announced the successful completion of Part A of the Phase 1/2 study and has initiated the Part B (Phase 2 proof-of-concept) study.
MNTA: 11.00 (-0.43)

Momenta Pharmaceuticals Announces Acceptance of a Clinical Trial Application in Europe for M923, a Biosimilar Version of Humira(R)
GlobeNewswire - Mon Dec 01, 7:00AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the acceptance by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a Clinical Trial Application (CTA) to initiate a clinical trial for M923, a biosimilar version of Humira (adalimumab), in its collaboration with Baxter International's biopharmaceutical business. Acceptance of the CTA triggers two milestones under the Baxter collaboration with an aggregate payment of $12 million. Momenta expects to receive the payment in December 2014.
BAX: 70.73 (-0.37), MNTA: 11.00 (-0.43)

Insider Trading Alert - MNTA, DOC And DSCI Traded By Insiders
at The Street - Fri Nov 28, 9:15AM CST
Stocks with insider trader activity include MNTA, DOC and DSCI
DSCI: 8.19 (-0.02), DOC: 15.71 (+0.06), MNTA: 11.00 (-0.43)

Momenta Pharmaceuticals to Webcast Presentation at 2014 Deutsche Bank BioFEST
GlobeNewswire - Mon Nov 24, 3:30PM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the 2014 Deutsche Bank BioFEST conference will be webcast on Monday, December 1 at 1:40 p.m. ET.
DB: 30.07 (+0.08), MNTA: 11.00 (-0.43)

Insider Trading Alert - MMLP, CTRL And MNTA Traded By Insiders
at The Street - Mon Nov 24, 9:15AM CST
Stocks with insider trader activity include MMLP, CTRL and MNTA
MMLP: 27.96 (+1.41), MNTA: 11.00 (-0.43), CTRL: 14.60 (-0.18)

Seres Health Appoints Biotechnology Finance Leader Eric Shaff as Chief Financial Officer
PR Newswire - Mon Nov 17, 8:00AM CST
Seres Health, Inc., a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that Eric Shaff has joined Seres as its Chief Financial Officer. Mr. Shaff will provide strategic financial guidance for Seres and manage the overall finances of the company.
MNTA: 11.00 (-0.43)

Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 6:39PM CST

MNTA: 11.00 (-0.43)

Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences
GlobeNewswire - Thu Nov 06, 7:42AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at three upcoming investor conferences.
MNTA: 11.00 (-0.43)

Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:15PM CST

MNTA: 11.00 (-0.43)

Momenta Pharmaceuticals, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 1:32PM CST
At this point, earnings calls for Momenta Pharmaceuticals are more an opportunity to update investors than to report revenue and earnings. Because, let's face it... sales of Momenta's and Novartis ' enoxaparin, a generic version of Sanofi 's ...
BAX: 70.73 (-0.37), TEVA: 55.15 (-0.47), ABBV: 65.25 (-0.37), SNY: 45.38 (+0.98), MNTA: 11.00 (-0.43), NVS: 91.65 (+0.01)

Momenta updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:03AM CST

MNTA: 11.00 (-0.43)

Momenta Pharmaceuticals (MNTA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 8:55AM CST

MNTA: 11.00 (-0.43)

Momenta misses 3Q profit forecasts
Automated Insights - Wed Nov 05, 8:09AM CST
CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Wednesday reported a third-quarter loss of $29.1 million.
MNTA: 11.00 (-0.43)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 16

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
Frontline Claims Survey Tests AI's Real Desk Impact

Updated Category News Views 92

Claims software can look brilliant in a conference-room demo and still create a fresh pile of headaches for the person handling a real injured worker’s file. That is why the 2026 Workers’ Compensation Benchmarking Study opening its survey to frontline claims professionals matters more than the usual industry questionnaire. This is an operating-reality check, not just...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 304

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 38

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 65

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 164

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 146

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 135

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 23

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Discount Tire’s $10 Correction Matters This Black Friday

Updated Category News Views 0

A ten-dollar correction is not a catastrophe, but it is precisely the sort of loose screw that deserves a glance before Black Friday shouting gets underway. Discount Tire says an earlier version of its Nov. 17, 2026 promotion release listed combined instant savings of $390 when the correct maximum is $380. The company issued the correction and supplied a revised release....

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring High ROIC Tech Stocks: Key Insights and Analysis

Updated Category News Views 284

Understanding ROIC in Tech Stocks Return on Invested Capital (ROIC) is a vital indicator when evaluating a company's financial performance and investment potential. It reflects how efficiently a firm uses the capital invested by shareholders to generate profits. High ROIC values signal that a company is not only effective in utilizing its resources but may also be poised...

Continue Reading
Join AVITA Medical's Upcoming Investor Webinar Event

Updated Category News Views 141

AVITA Medical Plans Informative Investor Webinar AVITA Medical, Inc. (NASDAQ: RCEL), known for its innovative approaches to acute wound care, is gearing up to host an insightful investor webinar. The CEO, Jim Corbett, alongside CFO, David O'Toole, will lead this engaging session and discuss the latest financial results and strategic business developments. Details of the...

Continue Reading
Labour Government's Budget Aims to Restore Market Stability

Updated Category News Views 138

Introduction to the New Labour Budget The newly formed Labour government has introduced its first budget, aiming to restore confidence in the UK markets. With a focus on substantial tax increases and strategic spending control, this budget seeks to avoid the destabilizing impact seen during Liz Truss's tenure. The measures announced are designed to bolster the economy...

Continue Reading
Beacon Energy to Host Annual General Meeting This December

Updated Category News Views 166

Beacon Energy's Annual General Meeting Update Beacon Energy plc (AIM: BCE, NYSE: BCE) is an oil and gas company dedicated to developing its onshore assets in Germany. Recently, the company confirmed that it is set to hold its Annual General Meeting (AGM) on December 18, 2024. This significant event will be hosted at 55 Athol Street, Douglas, Isle of Man, providing a prime...

Continue Reading
Okeanis Eco Tankers: Key Insights Ahead of Earnings Call

Updated Category News Views 130

Anticipating Okeanis Eco Tankers' Upcoming Earnings Okeanis Eco Tankers (NYSE:ECO) is preparing to release its latest quarterly earnings report soon. Investors and analysts are keenly focused on what this announcement will bring, particularly in terms of earnings expectations and guidance for upcoming quarters. Expected Earnings Report Industry analysts anticipate that...

Continue Reading